We found that plasma TP73‐AS1 and CRNDE levels increased progressively in the three groups of patients with NSCLC, although some increased levels failed to demonstrate statistically significant differences (such as stage I vs. stage II and stage II vs. stage III A; Figure S2C,D). Here, TP73 is linked to non-small cell lung carcinoma.